Tetrahydrobiopterin therapy for phenylketonuria in infants and young children.

Abstract

OBJECTIVE To describe patient selection, treatment administration, response evaluation, and side effect management associated with sapropterin therapy in infants and children aged <4 years. STUDY DESIGN Six case reports are presented from 4 US metabolic clinics treating phenylketonuria with sapropterin in patients aged 7 months to 4 years. Outcomes included blood phenylalanine (Phe) levels before and during treatment. For 3 of 6 cases, diet records were used to monitor changes in dietary Phe. RESULTS Severity of phenylketonuria ranged from mild to severe (classic). Treatment with sapropterin was safe and generally well tolerated. Blood Phe levels were reduced, or maximum dietary Phe tolerance was increased in patients with blood Phe that was well controlled by diet. CONCLUSIONS Given the increasing evidence that maintaining blood Phe levels below 360 μmol/L is important for the normal development of neurocognitive and behavioral function, sapropterin can be combined with a Phe-restricted diet to control blood Phe levels in young patients responsive to sapropterin therapy.

DOI: 10.1016/j.jpeds.2010.08.016

4 Figures and Tables

0501001502011201220132014201520162017
Citations per Year

159 Citations

Semantic Scholar estimates that this publication has 159 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Burton2011TetrahydrobiopterinTF, title={Tetrahydrobiopterin therapy for phenylketonuria in infants and young children.}, author={Barbara K. Burton and Darius J Adams and Dorothy Katherine Grange and John I. Malone and Elaina R. Jurecki and Heather Bausell and Kayt D Marra and Laurie Sprietsma and Kathleen T Swan}, journal={The Journal of pediatrics}, year={2011}, volume={158 3}, pages={410-5} }